

Richard Adams

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9055743/publications.pdf>

Version: 2024-02-01

14
papers

190
citations

1306789

7
h-index

1125271

13
g-index

15
all docs

15
docs citations

15
times ranked

264
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	3.0	2
2	Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. <i>Clinical Trials</i> , 2022, 19, 146-157.	0.7	7
3	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	3
4	Reply to A. Kurreck et al and M.S. Copur et al. <i>Journal of Clinical Oncology</i> , 2022, 40, 1263-1264.	0.8	0
5	A Road Map for Designing Phase I Clinical Trials of Radiotherapyâ€œNovel Agent Combinations. <i>Clinical Cancer Research</i> , 2022, 28, 3639-3651.	3.2	2
6	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	1.4	3
7	<i>BRAF</i> V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1386-1395.	3.0	17
8	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	3.0	12
9	Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). <i>Radiation Oncology</i> , 2021, 16, 163.	1.2	9
10	Inhibition of WEE1 Is Effective in <i>TP53</i> - and <i>RAS</i> -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. <i>Journal of Clinical Oncology</i> , 2021, 39, 3705-3715.	0.8	51
11	Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3693-3704.	0.8	19
12	HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 944-954.	3.0	11
13	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018, 100, 35-45.	1.3	29
14	Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. <i>European Journal of Cancer</i> , 2018, 102, 31-39.	1.3	25